Kalra Priyata, Kister Bastian, Fendt Rebekka, Köster Mario, Pulverer Julia, Sahle Sven, Kuepfer Lars, Kummer Ursula
Department of Modelling of Biological Processes, COS/BioQuant, Heidelberg University, Heidelberg, Germany.
Institute for Systems Medicine with Focus on Organ Interaction, University Hospital RWTH Aachen, Aachen, Germany.
PLoS Comput Biol. 2025 Sep 25;21(9):e1013509. doi: 10.1371/journal.pcbi.1013509. eCollection 2025 Sep.
Drug effects are difficult to investigate in detail in vivo. However, a mechanistic understanding of drug action is clearly beneficial for both pharmaceutical development as well as for optimization of treatment designs. We here established a quantitative systems pharmacology (QSP) mouse model which simultaneously describes whole-body pharmacokinetics of murine IFN-α as well as the cellular pharmacodynamic effect through the antiviral response biomarker Mx2. To this end, a dynamic model of intracellular IFN-α signalling in the JAK/STAT pathway was combined with a whole-body physiologically-based pharmacokinetic model of IFN-α in mice. The pharmacodynamic behaviour of the resulting mouse IFN-α QSP model was first compared to a cellular model of the JAK/STAT pathway to compare in vitro and in vivo drug effects and to identify functional differences. It was found that the in vitro drug effect in the cellular model overestimates the in vivo response in mice at least by a factor of two which is partly due to the missing drug clearance in vitro. Also, the drug responses in the in vitro model were time delayed. Interspecies analyses in murine and a previously published human QSP model of IFN-α next show a similar dynamic behavior. However, our models demonstrate eight to 16-fold stronger response levels in mice than in humans due to more efficient interferon binding. Our analysis supports a mechanistic analysis of both upstream pharmacokinetic as well as downstream pharmacodynamic drug effects through the combination of physiological knowledge and quantitative computational models. The study hence shows potential applications for QSP modelling in terms of study planning, for example by choosing physiologically relevant in vitro concentrations. Also, the QSP model allows inter-species comparisons of the effect strength in specific functional readouts, which in humans are otherwise not possible due to the limited sampling possibilities. We expect QSP modelling to play an increasingly important role in drug development and research in the future.
药物效应在体内难以进行详细研究。然而,从机制上理解药物作用显然有利于药物研发以及治疗方案的优化。我们在此建立了一个定量系统药理学(QSP)小鼠模型,该模型同时描述了小鼠IFN-α的全身药代动力学以及通过抗病毒反应生物标志物Mx2体现的细胞药效学效应。为此,将JAK/STAT途径中细胞内IFN-α信号传导的动态模型与小鼠IFN-α的全身生理药代动力学模型相结合。首先将所得小鼠IFN-α QSP模型的药效学行为与JAK/STAT途径的细胞模型进行比较,以比较体外和体内的药物效应,并确定功能差异。结果发现,细胞模型中的体外药物效应至少高估了小鼠体内反应两倍,部分原因是体外缺乏药物清除。此外,体外模型中的药物反应存在时间延迟。接下来,对小鼠和先前发表的人类IFN-α QSP模型进行种间分析,结果显示出类似的动态行为。然而,由于干扰素结合更有效,我们的模型显示小鼠的反应水平比人类强8至16倍。我们的分析支持通过结合生理学知识和定量计算模型对上游药代动力学以及下游药效学药物效应进行机制分析。因此,该研究展示了QSP建模在研究规划方面的潜在应用,例如通过选择生理相关的体外浓度。此外,QSP模型允许对特定功能读数中的效应强度进行种间比较,否则由于采样可能性有限,在人类中无法进行这种比较。我们预计QSP建模在未来的药物研发和研究中将发挥越来越重要的作用。